InvestorsHub Logo
Followers 1
Posts 104
Boards Moderated 0
Alias Born 05/18/2016

Re: None

Wednesday, 05/01/2019 11:06:40 AM

Wednesday, May 01, 2019 11:06:40 AM

Post# of 3059
"Building off a surprise success with Mavyret in adults, AbbVie has nabbed an FDA approval to market the hepatitis C drug for children ages 12 to 17. The drug — a combination of glecaprevir and pibrentasvir — racked up $3.438 billion in net revenue for 2018, far exceeding peak sales expectations. The OK was based on a trial of 47 HCV patients with genotypes 1-4 suggesting a 100% cure rate, though it covers all six genotypes." EndPoint News.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENTA News